Research Topics
| Elizabeth A MittendorfSummaryAffiliation: Walter Reed Army Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes
Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Dr, Fort Sam Houston, TX, 78234, USA
J Clin Oncol 26:3426-33. 2008..We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients...
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsyElizabeth A Mittendorf
Comprehensive Breast Center, Clinical Breast Care Project CBCP, Walter Reed Army Medical Center, Washington, DC 20307, USA
Curr Surg 62:253-7. 2005..The technique has also been applied successfully in patients with ductal carcinoma in situ (DCIS). The purpose of this study was to review our experience performing SLNB in patients with a biopsy diagnosis of DCIS...- Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptidesElizabeth A Mittendorf
Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
Breast Cancer Res Treat 92:85-93. 2005..57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional (51)Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials... - Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin
Department of Surgery, General Surgery Service, Walter Reed Army Medical Center, Washington, DC, USA
Cancer Immunol Immunother 57:1817-25. 2008..We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups... - Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancerElizabeth A Mittendorf
Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307-5001, USA
Ann Surg Oncol 13:1085-98. 2006..These findings support further investigation into the use of combination immunotherapy with trastuzumab and HER2/neu peptide-based vaccines... - The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides
Department of Surgery, General Surgery Service, Brooke Army Medical Center, Houston, Texas 78234, USA
Clin Cancer Res 15:2895-904. 2009..We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression. Vaccine response based on HER2/neu expression level was analyzed... - Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04Mark G Carmichael
Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
Cancer 116:292-301. 2010..GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented... - Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02George E Peoples
Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas 78234, USA
Clin Cancer Res 14:797-803. 2008..We have conducted two overlapping E75 vaccine trials to prevent recurrence in node-positive (NP) and node-negative (NN) breast cancer patients... - Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides
Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Ft Sam, Houston, TX 78234, USA
Expert Rev Vaccines 10:201-10. 2011..077) and GP2 (p = 0.076). All three peptide vaccines were safe and well-tolerated. These findings have led to a clinically relevant optimal vaccine dosing strategy, which may be applicable to other peptide-based cancer vaccines... - Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trialElizabeth A Mittendorf
Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
Cancer 106:2309-17. 2006..Importantly, GP2-specific effectors recognize 2VGP2-expressing targets; therefore, a GP2 vaccine should be effective in patients carrying this polymorphism. GP2 may be most beneficial used in a multiepitope vaccine... - The GP2 peptide: a HER2/neu-based breast cancer vaccineKevin S Clive
Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, Texas, USA
J Surg Oncol 105:452-8. 2012.... - Folate receptor α: a storied past and promising future in immunotherapyGuy T Clifton
Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, TX, USA
Hum Vaccin 7:183-90. 2011..This review will cover immunotherapeutic methods, both active and passive, that target FRα... - Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot studyAlexander Stojadinovic
Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
Ann Surg Oncol 14:3359-68. 2007..Recent advances in the ability to quantify and phenotype circulating tumor cells (CTCs) in breast cancer patients may lead to a role for CTCs in monitoring response to vaccine-based immunotherapy... - Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancerElizabeth A Mittendorf
Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307-5001, USA
Surgery 139:407-18. 2006..The ability to raise immunity to multiple tumor antigens depends on both the degree of HER2/neu expression and the extent of disease. Epitope spreading is an essential element for the success of a peptide vaccine strategy... - Cancer vaccines: should we be targeting patients with less aggressive disease?Diane F Hale
Department of Surgery, General Surgery Service, Brooke Army Medical Center, San Antonio, TX, USA
Expert Rev Vaccines 11:721-31. 2012..Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease... - Electrical impedance scanning as a new breast cancer risk stratification tool for young womenAlexander Stojadinovic
Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
J Surg Oncol 97:112-20. 2008..The T-Scan(tm2000 (ED is designed to use EIS to identify women ages 30-39 with elevated risk of breast cancer (i.e., T-Scan+ women)... - Surgical considerations in patients receiving neoadjuvant systemic therapyAkhil Chawla
Department of Surgery, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA
Future Oncol 8:239-50. 2012..An ongoing cooperative group trial is investigating the utility of sentinel lymph node surgery in the clinically node-positive population... - Satisfaction with breast cancer screening and future screening participationAlexander Stojadinovic
Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
Med Sci Monit 13:CR422-9. 2007.... - Staging of breast cancer in the neoadjuvant settingJacqueline S Jeruss
Department of Surgery, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Cancer Res 68:6477-81. 2008.... - Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidismElizabeth A Mittendorf
Department of Surgery, MetroHealth Medical Center, 2500 MetroHealth Dr, H920, Cleveland, OH 44109-1998, USA
Arch Otolaryngol Head Neck Surg 128:275-9. 2002..It is not a manifestation of persistent disease but is most likely a secondary response to bone remineralization... - Management of giant gastric ulcers: case report and review of the literatureJ Scott Kennedy
Department of Surgery, Malcolm Grow Medical Center, 1050 West Perimeter Road, Andrews Air Force Base, Maryland, USA
Curr Surg 61:220-3. 2004 - The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid diseaseElizabeth A Mittendorf
Department of Surgery, Uniformed Services, University of the Health Sciences, Bethesda, MD, USA
Surgery 132:648-53; discussion 653-4. 2002..05). CONCLUSIONS: US improves the diagnostic yield in selected patients with nondiagnostic standard FNAB. The higher frequency of nondiagnostic US-guided FNAB was related to its selective use in patients with smaller nodules... - Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes
Department of Medicine, Division of Hematology and Medical Oncology, Naval Medical Center San Diego, San Diego, California, USA
Cancer 113:1666-75. 2008..The optimal biologic dose (OBD) was determined based on toxicity and immunologic response... - The E75 HER2/neu peptide vaccineElizabeth A Mittendorf
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Cancer Immunol Immunother 57:1511-21. 2008..Finally, we present some of the future directions for our Cancer Vaccine Development Program assessing multi-epitope peptide vaccines and combination immunotherapies... - Significance and management of micrometastases in patients with breast cancerElizabeth A Mittendorf
The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
Expert Rev Anticancer Ther 7:1451-61. 2007.... - Breast cancer vaccines: promise for the future or pipe dream?Elizabeth A Mittendorf
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 110:1677-86. 2007..A second strategy for a preventive breast cancer vaccine is to target tumor-associated antigens. Ongoing clinical trials are utilizing this approach, with preliminary results that are encouraging... - Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapyJacqueline S Jeruss
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
J Clin Oncol 26:246-52. 2008..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...